Thursday, December 18, 2025 | 03:53 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

WHO halts trial of 2 drugs to treat hospitalised coronavirus patients

Hydroxychloroquine and lopinavir showed little or no reduction in the mortality, says the international organisation.

Hydroxychloroquine, coronavirus, covid-19, drug, drugs, pharma, pharmaceutical
premium

IANS Geneva
The World Health Organization (WHO) announced on Saturday that it was discontinuing trial of hydroxychloroquine and lopinavir/ritonavir drugs for treating Covid-19, citing little or no reduction in the mortality of hospitalised patients.

The WHO said the decision was in light of the evidence from the Solidarity Trial interim results.

"These interim trial results show that hydroxychloroquine and lopinavir/ritonavir produce little or no reduction in the mortality of hospitalized Covid-19 patients when compared to standard of care. Solidarity trial investigators will interrupt the trials with immediate effect," the WHO said in a press release, Xinhua reported.

WHO said this decision applies only to hospitalised